Loading...
•
Mar 31, 2022
Madrigal Q1 2022 Earnings Report
Madrigal reported first quarter 2022 financial results and provided clinical and business updates.
Key Takeaways
Madrigal Pharmaceuticals announced the acceptance of four abstracts for oral presentation at the EASL International Liver Congress and reported financial results for the first quarter of 2022. The company completed a $250 million term loan facility to support resmetirom clinical and commercial development.
MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress™
Data from the Phase 3 MAESTRO-NAFLD-1 study continue to reinforce the safety and efficacy profiles of resmetirom
Madrigal remains on track to disclose topline data from MAESTRO-NASH in the fourth quarter and anticipates filing for accelerated approval under Subpart H next year
Madrigal enters into term loan facility with ability to draw up to $250 million to support expansion of clinical development program and preparation for a potential U.S. launch of resmetirom
Madrigal
Madrigal
Forward Guidance
Madrigal plans to initiate a second NASH outcomes study, MAESTRO-NASH Outcomes, in the next few months and remains on track to disclose topline data from MAESTRO-NASH in the fourth quarter and anticipates filing for accelerated approval under Subpart H next year.